Chronic Urticaria and Inducible Urticaria
Jasper Therapeutics Inc. focuses on clinical research in chronic urticaria, including chronic spontaneous urticaria, chronic inducible urticaria, and related forms such as cold urticaria and symptomatic dermographism.
- Chronic Spontaneous Urticaria
- Chronic Inducible Urticaria
- Cold Urticaria
- Symptomatic Dermographism
The sponsor’s studies address persistent wheals, itching, and antihistamine-refractory symptoms in adult populations.
Allergic Asthma
The company also funds research in allergic asthma, reflecting interest in airway inflammation and allergic disease control.
- Allergic Asthma
- Asthma Symptom Control
- Allergic Airway Disease
This area extends the sponsor’s therapeutic focus beyond skin disorders to respiratory allergy-related conditions.
Briquilimab Clinical Development
Across its trial portfolio, Jasper Therapeutics is centered on briquilimab in immunology and allergic disease, with research examining safety, tolerability, and clinical activity in symptomatic patients.
- Briquilimab
- Immunology
- Allergic Disease
- Mast Cell-Related Disorders
The sponsor’s active studies are concentrated in the United States and involve multiple collaborating research sites.
